Tenofovir (all routes except local)

Limb defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5131
R13353		 Fowler, 2016 Musculoskeletal/Extremities malformations 2nd and/or 3rd trimester excluded randomized controlled trial exposed to other treatment, sick Adjustment: Randomisation Control group: zidovudine/lamivudine/lopinavir–ritonavir Exposed group: TDF/emtricitabine/lopinavir–ritonavir Indication: HIV 1.03 [0.06;16.46] C
excluded (exposition period) 		1/320   1/328 2 320
ref
S5128
R13332		 Sibiude, 2014 Limb and Musculoskeletal System 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No Control group: non-TDF (mix or unspecified regimens) Exposed group: TDF (mix or unspecified regimens) Indication: HIV 0.94 [0.46;1.92] -/823   -/12,043 - 823
ref
S5132
R13367		 Floridia, 2013 Muscoloskeletal defect and limb-reduction defects 1st trimester prospective cohort unexposed, sick Adjustment: No Control group: Unexposed, sick Exposed group: TDF (mix or unspecified regimens) Indication: HIV 0.36 [0.02;6.69] C 0/173   4/561 4 173
ref
Total 2 studies 0.89 [0.44;1.78] 4 996
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Sibiude, 2014Sibiude, 2014 0.94[0.46; 1.92]-82394%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Floridia, 2013Floridia, 2013 0.36[0.02; 6.69]41736%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.89[0.44; 1.78]49960.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.89[0.44; 1.78]49960%NASibiude, 2014 Floridia, 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.36[0.02; 6.69]4173 -NAFloridia, 2013 1 exposed to other treatment, sickexposed to other treatment, sick 0.94[0.46; 1.92]-823 -NASibiude, 2014 1 Tags Adjustment   - No  - No 0.89[0.44; 1.78]49960%NASibiude, 2014 Floridia, 2013 2 Control group   - non-TDF (mix or unspecified regimens)  - non-TDF (mix or unspecified regimens) 0.94[0.46; 1.92]-823 -NASibiude, 2014 1   - Unexposed, sick  - Unexposed, sick 0.36[0.02; 6.69]4173 -NAFloridia, 2013 1 Exposed group   - TDF (mix or unspecified regimens)  - TDF (mix or unspecified regimens) 0.89[0.44; 1.78]49960%NASibiude, 2014 Floridia, 2013 2 Indication   - HIV  - HIV 0.89[0.44; 1.78]49960%NASibiude, 2014 Floridia, 2013 2 All studiesAll studies 0.89[0.44; 1.78]49960%NASibiude, 2014 Floridia, 2013 20.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.36[0.02; 6.69]4173 -NAFloridia, 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.94[0.46; 1.92]-823 -NASibiude, 2014 10.510.01.0